Axsome Therapeutics Dismisses Patent Litigation with Sandoz
![Axsome Therapeutics Dismisses Patent Litigation with Sandoz](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Axsome Therapeutics and Sandoz Patent Litigation Agreement
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for central nervous system disorders, has reached an agreement with Sandoz Inc. to dismiss the patent litigation related to its product Sunosi (solriamfetol). The litigation was pending in the United States District Court for the District of New Jersey and originated from Sandoz's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for a generic equivalent of Sunosi. Following the withdrawal of Sandoz's ANDA, the litigation has been dismissed without prejudice.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is dedicated to developing and delivering innovative therapies for central nervous system (CNS) disorders that offer limited treatment options. The company is focused on creating therapeutic solutions with novel mechanisms of action to transform the treatment landscape for these conditions. Axsome is committed to advancing products that significantly enhance patient lives and provide new options for healthcare providers.
Company's Commitment to CNS Research and Development
Innovative Therapeutic Solutions
Through rigorous research and development, Axsome Therapeutics is dedicated to addressing the unmet needs of patients suffering from CNS disorders. The company’s portfolio includes promising candidates aimed at improving treatment outcomes and enhancing quality of life.
Focus on Market Needs
Axsome’s strategic initiatives are tailored to align with market demands, enabling the company to prioritize therapies that have a high impact on patient populations. This patient-centric approach ensures that the development process remains focused on delivering effective and safe treatment options.
Investor and Media Relations
For inquiries, investors and media representatives can reach out to the contacts below:
Investor Contact
Mark Jacobson
Chief Operating Officer
Axsome Therapeutics, Inc.
One World Trade Center, 22nd Floor
Tel: 212-332-3243
Email: mjacobson@axsome.com
Media Contact
Darren Opland
Director, Corporate Communications
Axsome Therapeutics, Inc.
One World Trade Center, 22nd Floor
Tel: 929-837-1065
Email: dopland@axsome.com
Frequently Asked Questions
What was the nature of the litigation between Axsome and Sandoz?
The litigation was related to a patent dispute concerning Axsome's product Sunosi by Sandoz, who sought to market a generic version.
Why was the patent litigation dismissed?
Sandoz withdrew its Abbreviated New Drug Application (ANDA), resulting in the dismissal of the litigation without prejudice.
What is Sunosi (solriamfetol) used for?
Sunosi is a medication developed by Axsome Therapeutics aimed at the treatment of certain sleep disorders, significantly aiding patients looking for relief from their symptoms.
What is Axsome Therapeutics' focus?
Axsome Therapeutics focuses on developing innovative treatments for central nervous system disorders, aiming to improve patient quality of life through novel therapeutic solutions.
Who can be contacted for more information about Axsome Therapeutics?
Interested parties can contact Mark Jacobson or Darren Opland through the provided email addresses for investor and media inquiries respectively.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/